← All trials
NCT01028170
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 1, 2009
- Primary completion
- Jul 1, 2011
- Completion date
- Jan 1, 2012
- First posted
- —
- Last posted
- —
- Enrollment
- 50
- Arms / groups
- 2 / —
- Source
- AACT · pre-existing
Sponsors
- Aspirus Heart and Vascular Institute-Research and EducationLead sponsor
- Aspirus Heart and Vascular Institute-Research and EducationOverall official - principal investigator
- Aspirus Heart and Vascular Institute-Research and EducationStudy director
- Aspirus Wausau HospitalCollaborator
- Aspirus Heart and Vascular Institute-Research and EducationReponsible party - principal investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.